Wheeze

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Blood pressure, Efgartigimod alfa, System, Urination, Urinary tract infection, MHLW, Chest pain, Rituximab, Allergy, Disease, Infection, Risk, Headache, Patient, Sore throat, IWG, History, ITP, Chills, Quality of life, Cough, Euronext, Rash, Respiratory tract infection, Splenectomy, Medicine, Skin, Fever, Antibody, Wheeze, Back pain, Shivering, Safety, Pain, Fatigue, Phlegm, Swelling, Food, Autoimmune disease, Nursing

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.

New Campaign Highlights How Certain Jobs Can Increase a Person's Risk for Lung Disease

Retrieved on: 
Tuesday, April 9, 2024
Pneumonia, Emphysema, Bronchitis, Disease, Tobacco, Agriculture, Risk, Urinary tract infection, Spirometry, Fatigue, Smoke, Quality of life, Sputum, Dust, Mucus, Smoking, Wheeze, American Lung Association, COPD, Air pollution, Workplace, Phlegm, Ageing, Mining, Nursing

CHICAGO, April 9, 2024 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) impacts 11.7 million people living in the U.S. While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD. To help people identify workplace risk factors and encourage them to speak with their healthcare provider if they are experiencing symptoms, the American Lung Association is launching a campaign to raise awareness for occupational COPD. 

Key Points: 
  • While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD.
  • COPD, which includes chronic bronchitis and emphysema, is a long-term lung disease that makes it hard to breathe.
  • Many workplaces may expose workers to risk factors for COPD, but the leading job types that increase risk for chronic lung disease include agriculture, mining and manufacturing.
  • Early treatment of a chronic lung disease, including reducing the exposure, can help lead to better health outcomes.

ChestPal™ Pro, a Bluetooth-Connected, Portable, Crackle and Wheeze Detection Innovation, Launches in the U.S. as Early Asthma and Allergy Season Looms

Retrieved on: 
Tuesday, March 12, 2024
Hardware, Health Technology, Health Insurance, Data Management, Other Health, Technology, Oncology, General Health, Biometrics, Medical Devices, Hospitals, Biotechnology, Software, Health, Medical Supplies, Mobile, Wireless, Diagnosis, MD, Wheeze, COPD, Patient, Lung, Multimedia, Asthma, Steroid, Classification, Pneumonia, Glimpse, Internal medicine, Entrepreneurship

ChestPal™ Pro, the only commercially available digital stethoscope in the U.S. that’s clinically backed to detect, classify, record, and share crackles and wheezes, launches to healthcare practitioners today.

Key Points: 
  • ChestPal™ Pro, the only commercially available digital stethoscope in the U.S. that’s clinically backed to detect, classify, record, and share crackles and wheezes, launches to healthcare practitioners today.
  • This press release features multimedia.
  • ​​For clinicians who need to accurately detect, record, and share classified lung sounds.
  • “ChestPal™ Pro helps pick up lung sounds that are too subtle to hear when using a stethoscope alone,” said Dr. Emily Tuchman, MD, General Internal Medicine.

ImmunoLytics: Plan Ahead for Spring Allergy Season

Retrieved on: 
Thursday, February 29, 2024
HVAC, Growth, HEPA, Health, Allergy, Spore, EPA, Wheeze, IEP, Pollen, Nose, Water, Cough

Albuquerque, NM, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spring is just around the corner, and for approximately 81 million people, that means allergy season.

Key Points: 
  • Albuquerque, NM, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spring is just around the corner, and for approximately 81 million people, that means allergy season.
  • If allergy sufferers also have mold sensitivity, that will exacerbate the situation.
  • To better prepare for the upcoming spring allergy season, people should test their homes to see if there is a mold issue.
  • ImmunoLytics Mold Check-Up™ costs $36 per room and is analyzed by the company’s lab team that looks for 37,000 species of mold.

Hugel Receives FDA Approval in the United States of Letybo (letibotulinumtoxinA-wlbg) for Injection for the Treatment of Glabellar Lines

Retrieved on: 
Monday, March 4, 2024
Food and Drug Administration, Headache, MD, AB toxin, Catherine Disher, FDA, Blinking, Food, Vitamin, Dizziness, Hugel & Fils, Risk, Allergy, Human, Telecanthus, Rash, Patient, Skin infection, Child, Bleeding, Medication, Wheeze, Face, Pharmaceutical industry

NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults. In the coming months, Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the back half of 2024.

Key Points: 
  • NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults.
  • This is a huge achievement for Hugel as we focus on becoming a top aesthetics brand in the U.S.," stated James Hartman, President, Hugel America.
  • Joely Kaufman, MD, commented, "The results from the clinical trials for letibotulinumtoxinA demonstrate efficacy, and a convincing safety profile in the treatment of glabellar lines1.
  • FDA approval is supported by positive results from three completed phase III trials that enrolled more than 1,000 subjects in the U.S. and Europe1.

BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs

Retrieved on: 
Wednesday, February 21, 2024
Allergy, ABBV, Senior, Woman, Injection, Research, ALS, Paratriathlon, Headache, Neck pain, Workplace, Education, Catherine Disher, Dream, Vitamin, Small business, Dizziness, Mentorship, Asthma, AbbVie, Weakness, Risk, AB toxin, Pain, Face, Human, COMMUNITY, BIPOC, Postal, Eyebrow, Confidence, Rash, Skin infection, Breast milk, Burnout, Myasthenia gravis, Eyelid, Lambert–Eaton myasthenic syndrome, Medication, Wheeze, Fatigue, Xerostomia, Partnership, Pharmaceutical industry

IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs. BOTOX® Cosmetic partnered with IFundWomen to launch the program in 2023, and in the second year, will award a new group of 20 women entrepreneurs each with $25,000 grants to fund and grow their businesses. Additionally, BOTOX® Cosmetic continues to support these businesses through mentorship, coaching, crowdfunding, and community.

Key Points: 
  • FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY
    IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs.
  • We are grateful to learn from them and thrilled to continue this program into a second year with a new cohort of extraordinary women entrepreneurs."
  • I am forever grateful to this program for connecting me to a group of women entrepreneurs who together are helping to bridge the Confidence Gap.
  • Starting today, women entrepreneurs across the country can apply for the BOTOX® Cosmetic x IFundWomen grant at www.botoxcosmetic.com/realimpact for the chance to be one of 20 recipients.

The Development of Allergic Disease Not Associated with Prenatal PM2.5 Air Pollution Exposure

Retrieved on: 
Friday, February 16, 2024
Wheeze, Incidence, Air pollution, AAAAI, Research, Food allergy, Multimedia, Asthma, Allergic rhinitis, Pregnancy, University, Health, Particulates, Patient, Journal, Dermatitis, American Academy, Cochineal

MILWAUKEE, Feb. 16, 2024 /PRNewswire-PRWeb/ -- No significant association was found between ambient particulate matter (PM2.5) exposure and incidences of asthma, allergic rhinitis or eczema according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting in Washington, DC this month.

Key Points: 
  • In settings of low overall air pollution levels, differences in the development of allergic disease by race were not significant in new birth cohort.
  • Black and Latin populations have been shown to have higher exposure to PM2.5 air pollution due to structural racism.
  • To assess the risks of prenatal air pollution exposure in minority populations, researchers recruited 1,261 mother-infant pairs from the University of Colorado.
  • The results found no evidence of an association between prenatal PM2.5 air pollution exposure and development of allergic disease or differences in air pollution exposure by race in a setting of low overall air pollution levels.

Non-Lesional Filaggrin Expression is Predictive of Asthma Development in Children with Atopic Dermatitis

Retrieved on: 
Wednesday, February 14, 2024
AAAAI, Research, Multimedia, TEWL, Atopic dermatitis, Parent, Skin, Risk, Mechanism, FLG, PFT, Patient, Journal, Diagnosis, Wheeze, Ageing, American Academy, Pharmaceutical industry

MILWAUKEE, Feb. 14, 2024 /PRNewswire-PRWeb/ -- Filaggrin (FLG) expression in non-lesional skin and observations of the skin barrier can lead to early diagnosis for children with asthma according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting, in Washington, DC, this month.

Key Points: 
  • Low Filaggrin expression in children aged 2 to 3 years old is a significant predictor of school-age asthma.
  • Specifically, filaggrin expression in the normal appearing skin predicts asthma development and is a better predictor than parent-report of physician-diagnosed asthma" says primary author Wan Chi Chang, MS.
  • In the study, pulmonary function testing (PFT) was conducted in 96 children, aged 7 to 8 years old, with atopic dermatitis from the Mechanisms of Progression from Atopic Dermatitis to Asthma in Children cohort.
  • Logistic regression evaluated the predictability of physician-diagnosed asthma reported by parents, transepidermal water loss (TEWL), SCORing Atopic Dermatitis (SCORAD) and skin expression of FLG for asthma.

Napp announces authorisation of REZZAYO® (rezafungin) in Great Britain by the UK Medicines and Healthcare Products Regulatory Agency for the treatment of invasive candidiasis in adults1

Retrieved on: 
Friday, February 2, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Multimedia, Hypokalemia, Tremor, Mortality, Mycology, Immunodeficiency, Hospice and palliative medicine, Nausea, MHRA, Immune system, UV, Candidiasis, Anemia, Caspofungin, Disease, Wheeze, Patient, Safety, DRC, Abdominal pain, Flushing, Diagnosis, Erythema, Hyponatremia, Rash, Sensation, Royal College of Pathologists, Radiation, Hypotension, Constipation, Risk, Vomiting, Restore, Medication, Phototoxicity, Infection, Medicine, Common, ODD, Diarrhea, Mitt, Pharmaceutical industry

Napp Pharmaceuticals Limited, a member of the international network of Mundipharma independent associated companies, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised rezafungin for the treatment of invasive candidiasis in adults in Great Britain (GB).1,2

Key Points: 
  • Napp Pharmaceuticals Limited, a member of the international network of Mundipharma independent associated companies, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised rezafungin for the treatment of invasive candidiasis in adults in Great Britain (GB).1,2
    This press release features multimedia.
  • Common adverse reactions include anaemia, hypomagnesaemia, hypophosphataemia, hypotension, wheezing, vomiting, nausea, abdominal pain, constipation, erythema, and rash.
  • Increased blood alkaline phosphatase, hepatic enzymes, alanine aminotransferase, aspartate aminotransferase and blood bilirubin were also common.
  • Transient infusion-related reactions have occurred with rezafungin, characterised by flushing, sensation of warmth, nausea, and chest tightness.2
    Rezafungin may cause increased risk of phototoxicity.

AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma

Retrieved on: 
Monday, January 22, 2024
FDA, Health, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Ageing, Budesonide, Potassium, Allergy, Swelling, Mouth, Patient, Cataract, Pneumonia, Rash, Approval, Wheeze, Multimedia, Cough, Face, Kidney, Hypokalemia, ICS, International, Fungal infection, Catherine Disher, Medicine, Risk, Immunology, Global Initiative for Asthma, Water, Periodic breathing, Disease, Inflammation, Tongue, OCS, Common, Glaucoma, Red, Treatment, Itch, Chest pain, Salbutamol, Headache, Cardiovascular disease, US6, Pharmaceutical industry

In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma.

Key Points: 
  • In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma.
  • In DENALI, AIRSUPRA had a similar onset of bronchodilation compared to albuterol in patients with mild to moderate asthma.2
    The approach to treating asthma symptoms with rescue has changed.
  • The 2023 Global Initiative for Asthma (GINA) report supports a rescue approach that treats both symptoms and inflammation together.
  • Now, with AIRSUPRA available we can provide patients, especially those on maintenance therapy, another rescue option for managing their breakthrough symptoms.